Related Experiment Video

Updated: May 29, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

An overview of candesartan in clinical practice

Zeeshan Khawaja1, Christopher S Wilcox

  • 1Division of Nephrology and Hypertension, Georgetown University Medical Center, 3800 Reservoir Road, Washington, DC, USA.

Expert Review of Cardiovascular Therapy
|September 1, 2011
PubMed

Insights

Hypertension management benefits from combination therapy, particularly with candesartan and hydrochlorothiazide. This approach effectively lowers blood pressure, improves patient compliance, and reduces cardiovascular risks.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Hypertension is a significant risk factor for cardiovascular and renal diseases.
  • The Joint National Committee 7 recommends two-drug combination therapy for stage 2 hypertension (≥160/100 mmHg).
  • Combination therapy enhances blood pressure control, improves compliance, and reduces morbidity and mortality.

Purpose of the Study:

  • To review the literature on candesartan-based therapies for hypertension.
  • To evaluate the role of candesartan in managing stroke, diabetes mellitus, and heart failure.
  • To assess the efficacy and tolerability of fixed-dose combination therapies.

Main Methods:

  • Literature review of studies on candesartan and thiazide diuretics.
  • Analysis of clinical trial data on combination antihypertensive therapy.
  • Evaluation of safety and tolerability profiles of candesartan/hydrochlorothiazide.

Main Results:

  • Angiotensin II receptor blockers (ARBs), like candesartan, are well-tolerated and effective for hypertension, heart failure, and diabetic renal disease.
  • Thiazide diuretics enhance the blood pressure-lowering efficacy of ARBs.
  • Fixed-dose combination of candesartan/hydrochlorothiazide demonstrates high efficacy, improved compliance, and good tolerability.

Conclusions:

  • Candesartan-based therapies, especially in fixed-dose combinations with hydrochlorothiazide, are highly effective for hypertension management.
  • Combination therapy offers significant benefits in lowering blood pressure and improving patient outcomes.
  • Candesartan-based treatments play a crucial role in managing complex cardiovascular conditions.

Related Concept Videos

Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...